Profound Medical (NASDAQ:PROF) (NASDAQ:PROF) is a Canadian-based medical technology company focused on the development and commercialization of innovative therapeutic devices for ablation of soft tissue. The company’s proprietary platforms leverage real-time imaging and computer-assisted treatment delivery to offer minimally invasive alternatives to traditional surgical approaches. Profound Medical’s solutions are designed to address conditions such as prostate cancer, benign prostatic hyperplasia, and uterine fibroids by providing targeted, image-guided tissue ablation.
The cornerstone of Profound Medical’s product portfolio is the TULSA-PRO® system, which combines transurethral ultrasound ablation with continuous magnetic resonance imaging (MRI) monitoring. This integration allows physicians to visualize treatment in real time, adjust parameters on the fly, and ensure thermal ablation is confined to the intended tissue. The company is also advancing research into additional indications and treatment models that may benefit from precise, image-guided energy delivery.
Founded in 2008 under its former name, Sonocare Medical, the company rebranded as Profound Medical in 2014 to reflect its broadened focus on image-guided therapy platforms. Headquartered in Vancouver, British Columbia, Profound Medical operates in key markets across North America, Europe, and select regions in Asia. The company holds or has filed patents covering core technologies, and it collaborates with leading academic institutions and clinical centers to validate and expand the applications of its systems.
Profound Medical is led by a management team with deep expertise in medical devices, imaging, and life sciences commercialization. The company’s board and executive leadership have a track record of guiding healthcare ventures through regulatory approvals, market launches, and strategic partnerships. Through its commitment to precision ablation technology, Profound Medical aims to improve patient outcomes, reduce recovery times, and offer cost-effective therapeutic alternatives for common urological and gynecological conditions.
